Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
19.64
-0.98 (-4.75%)
At close: Jun 2, 2026, 4:00 PM EDT
19.77
+0.13 (0.66%)
After-hours: Jun 2, 2026, 4:26 PM EDT
Bicara Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Bicara Therapeutics stock has a consensus rating of "Buy" and an average price target of $31.46. The average 1-year stock price forecast is 60.18% higher than the current stock price, while the lowest is $16 (-18.53%) and the highest is $46 (+134.22%).
Price Target: $31.46 (+60.18%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Bicara Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 9 | 9 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 14 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 2, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $16 → $18 | Hold | Maintains | $16 → $18 | -8.35% | Jun 2, 2026 |
| Wells Fargo | Wells Fargo | Hold Reiterates $25 → $16 | Hold | Reiterates | $25 → $16 | -18.53% | Jun 2, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $42 | Buy | Reiterates | $42 | +113.85% | Jun 1, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $30 | Buy | Maintains | $30 | +52.75% | May 26, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.56
from -2.52
EPS Next Year
-3.79
from -3.56
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | ||
| Avg | n/a | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.10 | ||
| Avg | -3.56 | ||
| Low | -4.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.